top 

LymphActivist's Site

Dedicated to Lymphedema Patients and the Therapists Who Treat Them

Efficacy of Lymphedema Treatment Protocols

Comments on Technology Assessment "Diagnosis and Treatment of Secondary Lymphedema".
Robert Weiss, MS, Lymphedema Patient Advocate

General Observations

The Many Faces of Lymphedema

Technology Assessments and Systematic Reviews

Randomized Clinical Trials Document Efficacy of Treatment Protocols

The following randomized clinical trials RCTs have been accepted for review by one or another of the systematic reviews listed above. There is credible evidence to show that every manual modality can benefit some population subset. Shown on the following table are the lead author and date of the RCT, the systematic review which used the RCT, characteristics of the trial cohort, modalities employed, summary results in terms of edema reduction and comments on the length of the trial or follow-up.

Reference

Study*

Population**

Modalities***

Reduction†

Comments

Andersen 2000

TBCKF

42-38 BCRL

CGE/CGE+MLD

60%/48% NS

3 Mos.

Badger 2000

BCF

83 Upper & Lower

CB+CG/CG

31%/16%

24 Wks.

Barclay 2006

F

BCRL

Aromatherapy

None

 

Bertelli 1991

TEKMF

60 BCRL ?c?10cm

CG/ CG+ESLD

17-21/16-17%

2-6 Mo.

Bertelli 1992

EM

120 BCRL?c?10cm

CG, IPC, ESLD

15/13%

2/6 Mo.

Boris 1998

C

128 LLLE

IPC/No IPC

43%/3% GLE

Genital LE

Carati 2003

TF

64 BCRL

LLLT/Placebo

-90/+32 mL

3 Mo.

Didem 2005

THF

53 BCRL for 3 Yr.

CDT+HT

56%

Short Term

Dini 1998

TCEHKF

80 BCRL < 1 Yr.

IPC

11%

Short Term

Földi 1996

C

150 BCRL+RC

CDT

Reduced DLA

2 Yr.

Hamner 2007

H

135 BCRL

CDT

42%

Short Term

Hayes 2008

T

32 BCRL

E

<1%

3 Mo.

Hornsby 1995

BCK

25

SLD, E/+ CG

36%, 86%

16 Wk.

Jahr 2008

T

21 BCRL

MLD+DO/MLD

-16/+13mL

Breast LE

Jeffs 2006

H

74 BCRL

CDT

5 to18%

1 Yr.

Johansson 1998

TCKF

28+12/12 BCRL

CG+SPC/MLD

7%+ 7%/15%

2.5 Yr.

Johansson 1999

C

38 BCRL

CB\CB+MLD/CB

26%\11/4%

Short Term

Kaviani 2006

TF

8 BCRL

LLLT/Sham

Favors LLLT

22 Wk.

Kessler 2003

T

21 Hindfoot Surgery

E+MLD/E

6%/0%

 

Koul 2007

H

138 BCRL

CDT, MLD, HT

-56, 41, 24%

1 Yr.

Kozanoglu 2009

T

47 BCRL

IPC+E/LLLT+E

LLLT fav. LT

12 Mo.

Maiya 2008

T

20 BCRL

LLLT+E/CG+E

 

10 Days

McKenzie 2003

TCF

14 BCRL

E

Nil

2 Mo.

McNeely 2004

TCF

50 BCRL

MLD+CB/CB

46%/16%

1 Mo.

Radakovic 1998

T

36 BCRL

MLD/IPC

0.9/2.24cm

Short Term

Shaw 2007

T

21 BCRL

WR/CG

7%

12 Wk.

Shaw 2007

T

51 BCRL Obese

WR+CB+CG/CG

WL—>Red

24 Wk.

Sitzia 2002

TF

28 BCRL

CB\MLD/SLD

34/22%

2 WK.

Szuba 2002-1

TCF

23 BCRL 12 Yrs.

CDT+IPC/CDT

30%/27%

40 Days.

Szuba 2002-2

TCF

25 BCRL 9.5 Yrs.

CDT+IPC/CDT

90/33mL

6 Mo.

Vignes 2006

H

357 BCRL

CDT

404 mL

Short Term

Vignes 2007

H

356 BCRL

CDT

67%

1 Yr.

Wilburn 2006

TH

10 BCRL 3-24 Yrs.

SM/IPC

+52/-208 mL

42 Days

Williams 2002

TCF

29 BCRL

MLD+SLD

71/30 mL

12 Wk.


* The review or systematic study which identified the RCT: C=CHBRP 2005; Erickson 2001; H=Hayes 2008; K=Kligman 2003; M= Megens 1998; T=Technology Assessment-McMasters;

** BCRL=breast cancer-related lymphedema; LLLE=lower-limb lymphedema; RC=recurrent cellulitis

*** CB=compression bandaging; CDT=complex decongestive therapy; CG=compression garment; CGE=compression garment plus exercise; DO=Deep Oscillation; E=exercise; ESLD=electrically-stimulated lymph drainage; HT=home therapy; IPC=intermittent pneumatic compression; MLD=manual lymph drainage; SM=simple massage; SP=standard physiotherapy; WR=weight reduction

† DLA=Dermatolymphangioadenitis; GLE=genital lymphedema; NS=not significant

Cohort Studies Show Efficacy of Combined Decongestive Therapy

Study

No.

Measure

Mean Decrease

CDT Modalities

Boris 1997

119

∆ Volume

-63 to -69%

MLD, CB, Exer., CG

Bunce 1994

25

∆ Volume

-50%

MLD, CB, CG, Exer.

Casley-Smith 1992

200

∆ Volume

-60 to -103%

MLD, CB, CG, Exer.

Ferrandez 1992

102

∆ Circumference

-40 to -60%

MLD, CB, IPC

Földi 1989

399

∆ Volume

-54%

MLB, CB, CG, Exer.

Hamner 2007

135

∆ Volume

-13%

MLD, CG, Exer.

Hinrichs 2004

14

∆ Volume LL

-60%

MLD, CB, CG, Exer.

Karadibak 2008

62

∆ Volume

-26%

MLD, CG, Exer.

Ko 1998

299

∆ Volume

-59 to -68%

MLD, CB, CG, Exer.

Szuba 2000

40

∆ Volume

-38 to -44%

MLD, CB, CG, Exer.

Vignes 2006

537

∆ Volume

-30%

MLD. CB, CG, Exer.

Wozniewski 2001

208

∆ Volume

-19 to -43%

MLD, CG, Exer. (+IPC)

Yamamoto 2007

82

∆ Volume

-59 to -73%

2-Phase CDT


Value of Repeated Intensive Course of Treatment

Prevention of Lymphedema

Initiation and Termination of Lymphedema Treatment

Lymphedema of the Head and Neck and Trunk

Intermittent Sequential Pneumatic Pumps

Lymphedema Treatment Provider Qualifications

Summation

The conclusions of the Technology Assessment are in essential agreement with the others performed over the last decade. Although there is a lack of high-level evidence in support of the de facto lymphedema treatment protocol of complex decongestive therapy, this multi-modal multi-phasic treatment has been found to be effective in treating tens of thousands of patients in the U.S., Europe and Australia over the last 50 years. It is important for Medicare to cover a variety of measurement and treatment modalities and to allow the treating physicians and treating therapists to determine which combination of modalities are indicated for each patient, to arrive at a written plan of treatment and to select the appropriate measurements to measure progress against that plan.

December 7, 2009